RecruitingPHASE1, PHASE2NCT05084430

Study of Pembrolizumab and M032 (NSC 733972)

Studying Anaplastic astrocytoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Alabama at Birmingham
Principal Investigator
James Markert, MD
The University of Alabama at Birmingham
Intervention
M032(drug)
Enrollment
28 enrolled
Eligibility
18 years · All sexes
Timeline
20222028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05084430 on ClinicalTrials.gov

Other trials for Anaplastic astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Anaplastic astrocytoma

← Back to all trials